Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MH004 cream in mild-to-moderate atopic dermatitis
CTR20220070Phase 2Completed
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing MH004 cream with Placebo MH004 cream (2 arms). Primary endpoint: Percent change in Eczema Area and Severity Index (EASI) from baseline at Week 4. Started Jan 2022; status: completed.
02
Drugs
tofacitinib etocomil
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20220070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220070.